Cargando…
HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer
Ovarian cancer is the most lethal gynecological malignancy. Recurrence and chemoresistance are tough challenges leading to poor prognosis. HJURP is a molecular chaperone of CENP-A, which is associated with aggressive progression in multiple tumors. However, the function of HJURP in ovarian cancer ha...
Autores principales: | Dou, Zhiyuan, Qiu, Chunping, Zhang, Xun, Yao, Shu, Zhao, Chen, Wang, Zixiang, Chu, Ran, Chen, Jingying, Chen, Zhongshao, Li, Rongrong, Wang, Kun, Liu, Penglin, Liu, Chang, Song, Kun, Kong, Beihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771849/ https://www.ncbi.nlm.nih.gov/pubmed/35173547 http://dx.doi.org/10.7150/ijbs.65589 |
Ejemplares similares
-
Evaluation of the prognostic value of lymphadenectomy for low-grade serous ovarian cancer: A case-control multicenter retrospective study
por: Chen, Zhongshao, et al.
Publicado: (2022) -
Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study
por: Chu, Ran, et al.
Publicado: (2022) -
TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
por: Qi, Gonghua, et al.
Publicado: (2021) -
Increased Expression of Holliday Junction-Recognizing Protein (HJURP) as an Independent Prognostic Biomarker in Advanced-Stage Serous Ovarian Carcinoma
por: Li, Lin, et al.
Publicado: (2018) -
FBLN5 is targeted by microRNA-27a-3p and suppresses tumorigenesis and progression in high-grade serous ovarian carcinoma
por: Li, Rongrong, et al.
Publicado: (2020)